title: Preoperative γ-glutamyl transpeptidase to platelet ratio (GPR) is an independent prognostic factor for HBV-related hepatocellular carcinoma after curative hepatic resection.
abstract: Liver fibrosis and cirrhosis is associated with the prognosis of patients with hepatocellular carcinoma (HCC) after treatment. The γ-glutamyl transpeptidase to platelet ratio (GPR) is reported to predict significant liver fibrosis and cirrhosis. The aim of this study was to investigate the predictive value of preoperative GPR on the recurrence and survival of patients with HCC who underwent curative hepatectomy.A retrospective review of demographics, medical records, and prognosis of patients with hepatitis B virus (HBV)-related HCC was performed. Overall survival (OS) and disease-free survival (DFS) were evaluated using Kaplan-Meier method, and the log-rank test was used to analyze differences in recurrence and survival. Univariate and multivariate analyses were used for significance of prognostic factor.A total of 357 patients with HBV-related HCC were included in this analysis. The preoperative GPR was associated with recurrence and survival rates, independent of HCC progression or tumor marker levels, in a multivariate analysis. OS was higher in patients with a GPR <0.84 versus ≥084 (5-year survival rates 58.6% vs. 38.5%; P < 0.001). DFS was also worse in patients with a GPR ≥0.84 than in those with GPR <0.84 (5-year recurrence rates 42.8% vs. 22.8%; P < 0.001).GPR score of ≥0.84 represents a major risk factor for the poor prognosis for HBV-related HCC after hepatic resection, and GPR served as an independent predictive factor for HBV-related HCC OS.
authors.affiliation: Department of Hepatobiliary Surgery, First Affiliated Hospital, Health Science Center, Xi'an Jiaotong University, Xi'an Department of General Surgery, Bazhong Central Hospital, Bazhong, People's Republic of China.
authors.forename: Wan-Li
authors.initials: WL
authors.lastname: Wang
authors.forename: Xing-Long
authors.initials: XL
authors.lastname: Zheng
authors.forename: Zhi-Yong
authors.initials: ZY
authors.lastname: Zhang
authors.forename: Ying
authors.initials: Y
authors.lastname: Zhou
authors.forename: Jie
authors.initials: J
authors.lastname: Hao
authors.forename: Gang
authors.initials: G
authors.lastname: Tang
authors.forename: Ou
authors.initials: O
authors.lastname: Li
authors.forename: Jun-Xi
authors.initials: JX
authors.lastname: Xiang
authors.forename: Zheng
authors.initials: Z
authors.lastname: Wu
authors.forename: Bo
authors.initials: B
authors.lastname: Wang
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000201:enzymology* / Q000601:surgery / Q000821:virology*; D005260:Female; D006498:Hepatectomy; D006509:Hepatitis B / Q000150:complications*; D006801:Humans; D008103:Liver Cirrhosis / Q000201:enzymology*; D008113:Liver Neoplasms / Q000201:enzymology* / Q000601:surgery / Q000821:virology*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010976:Platelet Count; D057234:Preoperative Period; D011379:Prognosis; D057216:Propensity Score; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D005723:gamma-Glutamyltransferase / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D005723:gamma-Glutamyltransferase